HRS Guidelines Bundle (free trial)

Evaluation and Management of Arrhythmic Risk in Neuromuscular Disorders

Heart Rhythm Society GUIDELINES Apps brought to you free pf charge, courtesy of Guideline Central. Enjoy!

Issue link:

Contents of this Issue


Page 49 of 49

Disclaimer is resource is for informational purposes only, intended as a quick-reference tool based on the cited source guideline(s), and should not be used as a substitute for the independent professional judgment of healthcare providers. Practice guidelines are unable to account for every individual variation among patients or take the place of clinician judgment, and the ultimate decision concerning the propriety of any course of conduct must be made by healthcare providers aer consideration of each individual patient situation. Guideline Central does not endorse any specific guideline(s) or guideline recommendations and has not independently verified the accuracy hereof. Any use of this resource or any other Guideline Central resources is strictly voluntary. Source Groh WJ, Bhakta D, Tomaselli GF, et al. 2022 HRS expert consensus statement on evaluation and management of arrhythmic risk in neuromuscular disorders. HeartRhythm. 2022;19(10):e61-e120. doi:10.1016/j.hrthm.2022.04.022 TEL: 407.878.7606 • FAX: 407.878.7611 Order additional copies at Copyright © 2023 All rights reserved HRSNMD04233b Abbreviations AD, autosomal dominant; AF, atrial fibrillation; AFL, atrial flutter; AR, autosomal recessive; AV, atrioventricular; BMD, Becker muscular dystrophy; BPM, beats per minute; CIED, cardiovascular implantable electronic device; CM, cardiomyopathy; CMR, cardiac magnetic resonance imaging ; COR, class of recommendation; CRM, cardiac rhythm management; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy with defibrillator; CRT-P, cardiac resynchronization therapy with pacemaker; DM, myotonic dystrophy; DM1, myotonic dystrophy type 1; DM2, myotonic dystrophy type 2; DMD, Duchenne muscular dystrophy; DMPK, myotonic dystrophy protein kinase; DUX4, double homeobox 4; ECG, electrocardiogram; EDMD, Emery-Dreifuss muscular dystrophy; EDMD1, Emery-Dreifuss muscular dystrophy type 1; EDMD2, Emery-Dreifuss muscular dystrophy type 2; EDMD3, Emery-Dreifuss muscular dystrophy type 3; EP, electrophysiological; FA, Friedreich ataxia; FSHD, facioscapulohumeral muscular dystrophy; GDMT, guideline-directed medical therapy; HCM, hypertrophic cardiomyopathy; ICD, implantable cardioverter-defibrillator; LBBB, le bundle branch block; LGMD, limb-girdle muscular dystrophy; LGMD1B, limb-girdle muscular dystrophy type 1B; LGMD2, limb-girdle muscular dystrophy type 2; LOE, level of evidence; LVEF, le ventricular ejection fraction; mtDNA, mitochondrial DNA; NMD, neuromuscular disorder; NYHA, New York Heart Association; PPM, permanent pacemaker; RBBB, right bundle branch block; RCT, randomized controlled trial; RV, right ventricular; VA, ventricular arrhythmia; VF, ventricular fibrillation; VT, ventricular tachycardia; XL, X-linked; ZNF9, zinc finger 9

Articles in this issue

Links on this page

Archives of this issue

view archives of HRS Guidelines Bundle (free trial) - Evaluation and Management of Arrhythmic Risk in Neuromuscular Disorders